Is there a role for dual PI3K/mTOR inhibitors for patients affected with lymphoma?
- Tarantelli, Chiara Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
- Lupia, Antonio Department of Health Sciences, University “Magna Græcia” of Catanzaro, Italy
- Stathis, Anastasios Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
- Bertoni, Francesco Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
-
05.02.2020
Published in:
- International journal of molecular sciences. - 2020, vol. 21, no. 3, p. 21 p
English
The activation of the PI3K/AKT/mTOR pathway is a main driver of cell growth, proliferation, survival, and chemoresistance of cancer cells, and, for this reason, represents an attractive target for developing targeted anti- cancer drugs. There are plenty of preclinical data sustaining the anti-tumor activity of dual PI3K/mTOR inhibitors as single agents and in combination in lymphomas. Clinical responses, including complete remissions (especially in follicular lymphoma patients), are also observed in the very few clinical studies performed in patients that are affected by relapsed/refractory lymphomas or chronic lymphocytic leukemia. In this review, we summarize the literature on dual PI3K/mTOR inhibitors focusing on the lymphoma setting, presenting both the three compounds still in clinical development and those with a clinical program stopped or put on hold.
- Language
-
- English
- Classification
- Medicine
- License
- CC BY
- Open access status
- gold
- Identifiers
-
- RERO DOC 328091
- DOI 10.3390/ijms21031060
- ARK ark:/12658/srd1319051
- Persistent URL
- https://n2t.net/ark:/12658/srd1319051
Statistics
Document views: 92
File downloads:
- Bertoni_ijms_2020.pdf: 140